J. Varthalitis

522 total citations
17 papers, 421 citations indexed

About

J. Varthalitis is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, J. Varthalitis has authored 17 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in J. Varthalitis's work include Cancer therapeutics and mechanisms (5 papers), Cancer Treatment and Pharmacology (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). J. Varthalitis is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Cancer Treatment and Pharmacology (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). J. Varthalitis collaborates with scholars based in Greece. J. Varthalitis's co-authors include A. Athanassiou, Dimitrios Pectasides, Nikolaos Ziras, Pavlos Papakotoulas, Anna Potamianou, J. Boukovinas, Maria V. Papadopoulou, Αthanasios Kotsakis, G. Stathopoulos and Vassilis Georgoulias and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Lung Cancer.

In The Last Decade

J. Varthalitis

15 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Varthalitis Greece 9 280 114 111 102 97 17 421
Jan H. Wong United States 8 282 1.0× 53 0.5× 184 1.7× 29 0.3× 143 1.5× 9 457
Vijay Kasturi United States 9 220 0.8× 86 0.8× 103 0.9× 77 0.8× 110 1.1× 33 395
Alessio Fabozzi Italy 13 264 0.9× 108 0.9× 63 0.6× 221 2.2× 90 0.9× 32 507
Nicholas J. Giacalone United States 15 258 0.9× 173 1.5× 295 2.7× 216 2.1× 83 0.9× 25 721
Dominique Berton France 11 365 1.3× 74 0.6× 82 0.7× 78 0.8× 54 0.6× 35 481
Rebecca Tay United Kingdom 11 412 1.5× 211 1.9× 68 0.6× 88 0.9× 61 0.6× 22 512
Elisa Andrini Italy 11 287 1.0× 175 1.5× 33 0.3× 114 1.1× 63 0.6× 36 412
Claudia von Arx Italy 11 219 0.8× 78 0.7× 31 0.3× 100 1.0× 70 0.7× 31 461
Miaoyan Wei China 9 293 1.0× 100 0.9× 86 0.8× 250 2.5× 214 2.2× 24 524

Countries citing papers authored by J. Varthalitis

Since Specialization
Citations

This map shows the geographic impact of J. Varthalitis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Varthalitis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Varthalitis more than expected).

Fields of papers citing papers by J. Varthalitis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Varthalitis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Varthalitis. The network helps show where J. Varthalitis may publish in the future.

Co-authorship network of co-authors of J. Varthalitis

This figure shows the co-authorship network connecting the top 25 collaborators of J. Varthalitis. A scholar is included among the top collaborators of J. Varthalitis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Varthalitis. J. Varthalitis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Potamianou, Anna, et al.. (2012). Methotrexate, etoposide, ifosfamide and cisplatin (MVIP): An effective salvage therapy for patients with refractory or relapsed germ-cell tumors.. PubMed. 7(4). 337–45.
2.
Potamianou, Anna, et al.. (2012). Methotrexate, etoposide, ifosfamide and cisplatin (MVIP): an effective first-line therapy for IGCCC intermediate / poor prognosis patients with germ-cell tumors. Single institution experience.. PubMed. 7(1). 35–41.
3.
Stathopoulos, G., K. Syrigos, Gerasimos Aravantinos, et al.. (2006). A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer. 95(5). 587–592. 167 indexed citations
4.
Kakolyris, Stylianos, Nikolaos Ziras, Lambros Vamvakas, et al.. (2006). Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II study. Lung Cancer. 54(3). 347–352. 14 indexed citations
5.
Agelidou, Athina, M. Agelidou, J. Varthalitis, et al.. (2005). Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: A multicentre phase II study. Lung Cancer. 49(2). 241–244. 5 indexed citations
6.
Georgoulias, Vassilis, K. Syrigos, M. Agelidou, et al.. (2005). Docetaxel in combination with gemcitabine (DG) versus docetaxel (D) as front-line treatment in patients with advanced/metastatic NSCLC: A multicentre, randomized, phase III trial. Journal of Clinical Oncology. 23(16_suppl). 7052–7052. 3 indexed citations
7.
Agelaki, Sofia, J. Boukovinas, J. Varthalitis, et al.. (2004). A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer. Oncology. 66(3). 192–196. 12 indexed citations
8.
Potamianou, Anna, A. Polyzos, J. Boukovinas, et al.. (2004). Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as 1st line treatment in patients with ovarian cancer: A multicenter phase II clinical trial. Journal of Clinical Oncology. 22(14_suppl). 5108–5108. 3 indexed citations
9.
Pectasides, D., et al.. (1998). Paclitaxel in Cisplatin or Carboplatin-Pretreated Ovarian Cancer. Oncology. 55(3). 228–234. 8 indexed citations
10.
11.
Pectasides, Dimitrios, et al.. (1997). CEA, CA 19-9, and CA-50 in Monitoring Gastric Carcinoma. American Journal of Clinical Oncology. 20(4). 348–353. 69 indexed citations
12.
Pectasides, D., et al.. (1997). Comparison of Two Different Doses of Ondansetron plus Dexamethasone in the Prophylaxis of Cisplatin-lnduced Emesis. Oncology. 54(1). 1–6. 9 indexed citations
13.
14.
Athanassiou, A., et al.. (1997). Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer.. PubMed. 18(5). 420–5. 1 indexed citations
15.
Pectasides, Dimitrios, Faye Antoniou, L. Gogou, et al.. (1996). TPA, TATI, CEA, AFP, β-HCG, PSA, SCC, and CA 19-9 for Monitoring Transitional Cell Carcinoma of the Bladder. American Journal of Clinical Oncology. 19(3). 271–277. 54 indexed citations
16.
Pectasides, Dimitrios, et al.. (1995). Chemotherapy for Merkel Cell Carcinoma with Carboplatin and Etoposide. American Journal of Clinical Oncology. 18(5). 418–420. 34 indexed citations
17.
Pectasides, Dimitrios, et al.. (1989). Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. British Journal of Cancer. 60(4). 627–629. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan H. Wong Breakdown of academic impact, for papers by Vijay Kasturi Breakdown of academic impact, for papers by Alessio Fabozzi Breakdown of academic impact, for papers by Nicholas J. Giacalone Breakdown of academic impact, for papers by Dominique Berton Breakdown of academic impact, for papers by Rebecca Tay Breakdown of academic impact, for papers by Elisa Andrini Breakdown of academic impact, for papers by Claudia von Arx Breakdown of academic impact, for papers by Miaoyan Wei
Rankless by CCL
2026